Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of Clinical Investigation https://doi.org/10.1172/JCI188817 Dr. Alireza Raissadati et al.
Points
- Immune checkpoint inhibitors can cause ICI-myocarditis (ICI-m), a rare but lethal immune-related adverse event with up to 40% mortality.
- Clonally expanded Temra CD8+ T cells are identified as drivers of ICI-m, leading to lymphocyte and macrophage infiltrates.
- Current diagnostic methods are often nonspecific, insensitive, or invasive, highlighting the need for better biomarkers.
- Researchers developed a cell-free mRNA platform for high-resolution assessment of tissue damage and immune activity.
- This platform successfully captured Temra CD8+ T cell response and cardiomyocyte damage, demonstrating its ICI-m diagnostic potential.
Summary
This research developed and validated a novel plasma cell-free mRNA (cf-mRNA) platform for high-resolution assessment of tissue damage and immune activity in immune checkpoint inhibitor–induced myocarditis (ICI-m). ICI-m represents a rare but highly lethal immune-related adverse event (irAE) of cancer immunotherapy, with a reported mortality rate of up to 40%. Current diagnostic methods, including cross-sectional imaging, biochemical markers, and endomyocardial biopsy, are often nonspecific, insensitive, or highly invasive, underscoring an urgent clinical need for more disease-specific biomarkers.
Recent studies have implicated clonally expanded cytotoxic terminally differentiated effector memory CD8+ T cells reexpressing CD45RA (Temra CD8+ T cells) as the primary drivers of ICI-m, characterized histopathologically by lymphocyte- and macrophage-rich myocardial infiltrates. Traditional cf-mRNA analyses have lacked the necessary cell-type granularity to accurately map these disease-specific transcriptomic profiles from a “liquid biopsy.” This study addressed this limitation by developing a cf-mRNA platform capable of capturing the high-resolution tissue-specific information required.
The developed cf-mRNA platform was validated in a cohort of patients with ICI-m. The approach successfully captured both the disease-specific Temra CD8+ T cell immune response and the consequent cardiomyocyte damage. This demonstrates the significant potential of cf-mRNA disease profiling for ICI-m, offering a non-invasive, sensitive, and specific diagnostic tool. This platform could revolutionize early and accurate diagnosis, risk stratification, and potentially guide targeted therapies for this challenging and often fatal irAE, thereby improving patient outcomes.
Link to the article: https://www.jci.org/articles/view/188817
References
Raissadati, A., Zhou, X., Chou, H., Huang, Y. V., Khatua, S., Sun, Y., Xu, A., Loa, S., Hernandez, A., Zhu, H., & Wu, S. M. (2025). Using plasma cell-free mRNA to profile immune response and myocardial damage in immune checkpoint inhibitor–induced myocarditis. The Journal of Clinical Investigation, 135(16). https://doi.org/10.1172/JCI188817
